On March 15, 2024, Dan Chevallard informed Viracta Therapeutics, Inc. that he was resigning from his positions as Chief Financial Officer of the Company, effective on March 20, 2024, to pursue other opportunities. The Company thanks Mr. Chevallard for his many contributions to the Company over the last four years, eight months. In connection with Mr. Chevallard?s resignation, the Company entered into a consulting agreement with Mr. Chevallard pursuant to which he will provide certain transition services to the Company.

Effective upon Mr. Chevallard?s resignation as Chief Financial Officer, Melody Burcar, the Company?s Senior Vice President of Finance, will serve as the Company?s interim principal financial officer. Melody Burcar, MBA, CPA, 41, was promoted to the Company?s Senior Vice President of Finance, effective March 18, 2024, and previously served as the Company?s Vice President of Finance since September 2022. Previously, Ms. Burcar served as the Vice President of Finance and Corporate Controller at Secura Bio, Inc., a pharmaceutical company, from July 2019 to September 2022.

Prior to joining Secura Bio, Inc., Ms. Burcar held various finance and accounting roles in life science and medical device companies including Synthetic Genomics, Inc., a biotechnology company, from September 2014 to June 2019, and Ortho Organizers, a medical device company, from September 2009 to September 2014. Ms. Burcar began her career at Deloitte, spending 5 years in their assurance services practice. Ms. Burcar holds a B.S. in accounting from the University of San Diego and a M.B.A. from University of California, San Diego.

Ms. Burcar is a Certified Public Accountant in the state of California.